Drugs / adipose-derived mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03865394 | Jul 2019 → Mar 2021 | ulcer of lower limbs | Medical University of Warsaw | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose-derived mesenchymal stem cells | “The aim of this study is to investigate efficiency of applying of adipose-derived mesenchymal stem cells (ADSC) in treatment of chronic wounds in diabetic foot syndrome.” NCT03865394 ↗ |
| Known as | ADSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03865394 ↗ |
| Modality | Cell therapy | “human allogeneic adipose-derived mesenchymal stem cells (ADSC) cells” NCT03865394 ↗ |
| Route | Other | “applied directly onto prepared wound bed” NCT03865394 ↗ |